{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreid6p5ip4qqne7lftga5mjtq7nuek464ynp6myzw3pc2sacdpqynam",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mgxk57xzlsz2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreihinycgrp4wkg6to3yyvfotpo5t3r772mf27fngjgdc3d6pfr5pxu"
    },
    "mimeType": "image/jpeg",
    "size": 104866
  },
  "path": "/news/2026-03-cdk46-egfr-blockade-pancreatic-cancer.html",
  "publishedAt": "2026-03-13T14:00:01.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 inhibition offers an indirect strategy to counter KRAS-driven malignancy without direct KRAS targeting.",
  "title": "Study finds CDK4/6 plus EGFR blockade kills pancreatic cancer cells without KRAS drugs"
}